{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:02:07Z","timestamp":1791061327665,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      To investigate the efficacy and safety of vonoprazan based bismuth-containing quadruple therapy (VBCQ) in eradicating\n                      <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">Hp<\/jats:italic>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>The VBCQ and the proton pump inhibitor-based bismuth-containing quadruple regimen (PBCQ) were compared by retrieving relevant studies in Pubmed, Embase, Cochrane Library, CNKI, and Wanfang data. Combined analysis was performed with risk ratio (RR) and 95% CI as effect values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 10 studies were enrolled, including 7 randomized controlled trials and 3 cohort studies. In intention-to-treat analysis, the eradication rate of VBCQ (89.24%, 1103\/1236) was significantly higher than that of PBCQ (84.03%, 1021\/1215), with RR = 1.06 (95% CI: 1.03~1.10). In per-protocol analysis, the eradication rates of VBCQ and PBCQ were 92.94% (895\/963) and 87.82% (829\/944), respectively, with a significant difference (RR = 1.06, 95% CI: 1.03~1.09). Subgroup analysis of study design types shared similar results. VBCQ and PBCQ showed an incidence of adverse reactions of 37.30% (304\/815) and 34.94% (282\/807), respectively. Significant differences were not found between the two groups (RR = 1.07, 95% CI: 0.96-1.19), nor in subgroup analysis. The good compliance rates in VBCQ and PBCQ groups were 94.32% (216\/229) and 95.13% (215\/226), respectively, with no significant difference (RR = 0.99, 95% CI: 0.95~1.04).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>VBCQ has a higher eradication rate on Hp than PBCQ, while its adverse reactions and compliance are similar to PBCQ. However, we conservatively believe that in Hp eradication, the VBCQ is not inferior to PBCQ because of the small absolute difference.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mcg.0000000000002001","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T14:00:29Z","timestamp":1712930429000},"page":"950-956","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Vonoprazan is Not Inferior to Proton Pump Inhibitors in Bismuth-containing Quadruple Therapy for Helicobacter pylori Eradication"],"prefix":"10.1097","volume":"58","author":[{"given":"Yujie","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Xiangyang No. 1 People\u2019s Hospital, Hubei University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Medical College of Hubei University of Arts and Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Fourth Clinical College of Hubei University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangyang No. 1 People\u2019s Hospital, Hubei University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.12998\/wjcc.v10.i19.6349","article-title":"Current guidelines for Helicobacter pylori treatment in East Asia 2022: differences among China, Japan, and South Korea","volume":"10","author":"Cho","year":"2022","journal-title":"World J Clin Cases"},{"key":"R2-20250613","first-page":"150","article-title":"Chinese Society of Gastroenterology, Chinese Medical Association. 2022 Chinese National Clinical Practice Guideline on Helicobacter pylori eradication treatment","volume":"27","year":"2022","journal-title":"Chin J Dig"},{"key":"R3-20250613","first-page":"e15165","article-title":"Association between helicobacter pylori and gastric carcinoma","volume":"13","author":"Padda","year":"2021","journal-title":"Cureus"},{"key":"R4-20250613","first-page":"gutjnl-2022","article-title":"Management of helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"8","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5009\/gnl20288","article-title":"Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020","volume":"15","author":"Jung","year":"2021","journal-title":"Gut Liver"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2169\/internalmedicine.2521-18","article-title":"Efficacy of vonoprazan for Helicobacter pylori eradication","volume":"59","author":"Kiyotoki","year":"2020","journal-title":"Intern Med"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study","volume":"65","author":"Murakami","year":"2016","journal-title":"Gut"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/antibiotics12020346","article-title":"The efficacy and safety of vonoprazan and amoxicillin dual therapy for Helicobacter pylori infection: a systematic review and network meta-analysis","volume":"12","author":"Liu","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2288-8-22","article-title":"Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies","volume":"8","author":"Lundh","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R12-20250613","first-page":"78","article-title":"Clinical analysis of effect of the four combination therapy of voronorasen in elderly patients with peptic ulcer complicated with Helicobacter pylori infection","volume":"44","author":"Du","year":"2023","journal-title":"J Medical Forum"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"e12940","DOI":"10.1111\/hel.12940","article-title":"Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: a single-center, open-label, noninferiority, randomized controlled trial","volume":"28","author":"Lu","year":"2023","journal-title":"Helicobacter"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/cpdd.1276","article-title":"Pharmacokinetics, safety, and tolerability of vonoprazan or esomeprazole-based bismuth-containing quadruple therapy: a phase 1, double-blind, parallel-group study in adults with Helicobacter pylori infection in China","volume":"12","author":"Miao","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1751-2980.13166","article-title":"Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a propensity score matching analysis","volume":"24","author":"Wang","year":"2023","journal-title":"J Dig Dis"},{"key":"R16-20250613","first-page":"691","article-title":"Effect of vonoprazan on patients with initial infection of Helicobacter pylori","volume":"44","author":"Xie","year":"2023","journal-title":"Acad J Naval Med University"},{"key":"R17-20250613","article-title":"Effect of quadruple therapy with vonoprazan on eradication of Helicobacter pylori infection","author":"Zhong","year":"2023","journal-title":"Chin J New Drugs Clin Remedies"},{"key":"R18-20250613","first-page":"789","article-title":"Observation of efficacy of a novel potassium-competitive acid blockers vonoprazan in the treatment of Hp infection.","volume":"30","author":"Deng","year":"2022","journal-title":"Chin J Integr Trad West Med Dig"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bcp.14934","article-title":"Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication","volume":"88","author":"Huh","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R20-20250613","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/jgh.15837","article-title":"Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients","volume":"37","author":"Hou","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"R21-20250613","first-page":"42","article-title":"A randomized, double-blind, phase 3 study to evaluate the efficacy and safety of vonoprazan-based versus esomeprazole-based bismuth-containing quadruple therapy for the eradication of Helicobacter pylori infection in China. United European","volume":"10","author":"Song","year":"2022","journal-title":"Gastroenterol J"},{"key":"R22-20250613","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/23744235.2019.1588472","article-title":"Helicobacter pylori: molecular basis for colonization and survival in gastric environment and resistance to antibiotics. A short review","volume":"51","author":"Fagoonee","year":"2019","journal-title":"Infect Dis (Lond)"},{"key":"R23-20250613","first-page":"11","article-title":"Nocturnal acid breakthrough-approach to management","volume":"6","author":"Tutuian","year":"2004","journal-title":"MedGenMed"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"759249","DOI":"10.3389\/fphar.2021.759249","article-title":"Influence of cytochrome P450 2C19 genotype on Helicobacter pylori proton pump inhibitor-amoxicillin-clarithromycin eradication therapy: a meta-analysis","volume":"12","author":"Morino","year":"2021","journal-title":"Front Pharmacol"},{"key":"R25-20250613","doi-asserted-by":"crossref","first-page":"938419","DOI":"10.3389\/fphar.2022.938419","article-title":"Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: an updated meta-analysis","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Pharmacol"},{"key":"R26-20250613","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","article-title":"Vonoprazan: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"R27-20250613","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","article-title":"The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations","volume":"55","author":"Echizen","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R28-20250613","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s10620-017-4866-6","article-title":"Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases","volume":"63","author":"Yang","year":"2018","journal-title":"Dig Dis Sci"},{"key":"R29-20250613","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-20250613","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5056\/jnm18029","article-title":"Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases","volume":"24","author":"Oshima","year":"2018","journal-title":"J Neurogastroenterol Motil"},{"key":"R31-20250613","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/apt.14130","article-title":"Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication","volume":"46","author":"Jung","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R32-20250613","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000504939","article-title":"Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis","volume":"102","author":"Shinozaki","year":"2021","journal-title":"Digestion"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000002001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T18:04:31Z","timestamp":1749837871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000002001"}},"subtitle":["A Meta-analysis of 10 Studies From East Asia"],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0000000000002001","relation":{},"ISSN":["1539-2031"],"issn-type":[{"value":"1539-2031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]}}}